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USMLE Step 2 - 1 
A 57-year-old female with a history of hypertension comes to the 
physician because of shortness of breath. She says that she has been 
experiencing progressively worsening dyspnea while climbing the stairs 
in her house. She denies both chest pain and dyspnea at rest. She 
appears comfortable at rest. She is on aspirin and metoprolol. Physical 
examination shows a regular heart rate and rhythm with absence of 
murmurs or rubs but does have an S4. Blood pressure is 150/80 mm Hg 
and pulse 55/min. Pulmonary exam reveals rales at the bases. She has 
lower extremity edema. Echocardiogram shows increased LV filling 
pressures with a normal ejection fraction. Which of the following is the 
next best step? 
A. Candesartan, B. Digoxin, C. Reduce the dose of metoprolol, 
D. Verapamil, E. Transesophageal echocardiography 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE Step 2 - 2 
The correct answer is A -1 
This patient has been diagnosed with diastolic left ventricular 
dysfunction as a result of long-standing hypertension. The chronic 
effects of advanced hypertrophy in response to long-standing 
hypertension are the most likely cause of diastolic left ventricular 
dysfunction. The concentric hypertrophy leads to a heart that cannot 
relax during diastole, which manifests clinically as dyspnea on exertion. 
The best way to counteract the symptoms of diastolic left ventricular 
dysfunction is to administer a negative inotropic agent in an attempt to 
relax the heart during diastole, thus improving filling pressures. The goal 
heart rate is 55–60. If you push the heart rate down, the heart spends 
more time in diastole and has more time for diastolic filling. Therefore, 
you would not want to decrease the dose of metoprolol (Choice C). You 
may also use cardiac calcium channel blockers, such as verapamil or 
diltiazem (Choice D), but you would not want to push the HR <55. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE Step 2 - 2 
The correct answer is A - 2 
This patient has been diagnosed with diastolic left ventricular 
dysfunction as a result of long-standing hypertension. The chronic 
effects of advanced hypertrophy in response to long-standing 
hypertension are the most likely cause of diastolic left ventricular 
dysfunction. The concentric hypertrophy leads to a heart that cannot 
relax during diastole, which manifests clinically as dyspnea on exertion. 
The best way to counteract the symptoms of diastolic left ventricular 
dysfunction is to administer a negative inotropic agent in an attempt to 
relax the heart during diastole, thus improving filling pressures. The goal 
heart rate is 55–60. If you push the heart rate down, the heart spends 
more time in diastole and has more time for diastolic filling. Therefore, 
you would not want to decrease the dose of metoprolol (Choice C). You 
may also use cardiac calcium channel blockers, such as verapamil or 
diltiazem (Choice D), but you would not want to push the HR <55. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE Step 2 - 3 
The correct answer is A - 2 
• In addition to decreasing the heart rate, reducing the afterload with 
ACE inhibitors or ARBs is also a target for therapy. 
Candesartan (Choice A) has been shown to improve exercise 
tolerance but not mortality in patients with diastolic dysfunction. 
• Digoxin (Choice B) has not shown benefit in isolated diastolic heart 
failure and should not be used unless required for the treatment of 
coexisting atrial arrhythmias. 
• Transesophageal echocardiography (Choice E) is not indicated for 
diastolic left ventricular dysfunction because a transthoracic echo is 
sufficient to make the diagnosis, which involves documentation of 
normal or only minimally reduced left ventricular systolic function 
and evidence of abnormalities of left ventricular relaxation. One of 
the indications for transesophageal echo is to determine the 
presence of a thoracic aortic aneurysm. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
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Definition  
• Hypertension (HT), also known as high blood (BP) 
pressure, is a long term medical condition in 
which the blood pressure in the arteries is 
persistently elevated 
• HT defined as values >140 mmHg systolic BP 
(SBP) and/or >90 mmHg diastolic BP (DBP), based 
on the evidence from randomized control trials 
(RCTs) that in patients with these BP values 
treatment-induced BP reductions are beneficial  
https://en.wikipedia.org/wiki/Hypertension 
Epidemiology 1 
(Mean Systolic Blood Pressure, Females, Ages 
25+) 
http://image.slidesharecdn.com/bppowerpointwhd2013final-130411023015-phpapp02/95/blood-pressure-world-health-day-2013-13-638.jpg?cb=1365647502 
Epidemiology 2 
(Mean Systolic Blood Pressure, Males, Ages 25+) 
http://www.bettycjung.net/BG2013/GlobalBPmen2008.png 
Epidemiology 3 
(Prevalence of High Blood Pressure in USA) 
cdc.gov  
Epidemiology 4 
http://eurheartj.oxfordjournals.org/content/35/6/353 
Percent prevalence, awareness, 
treatment, and control of HT in 
urban and rural communities from 
high-, middle-, and low-income 
countries.   HT controlled is 
defined as the proportion of 
participants with HT with SBP < 
140 and DBP < 90 mmHg. HIC, 
high-income countries; UMIC, 
upper middle-income countries; 
LMIC, lower middle-income 
countries; LIC, low-income 
countries  
Risk Factors 
healthy-ojas.com/assets/highbp/highbp-risk-factors.jpg 
Etiology 1   
• HT is classified as either primary (essential) or 
secondary  
• About 90–95% of cases are primary, defined as high 
blood pressure due to nonspecific lifestyle and genetic 
factors (lifestyle factors that increase the risk include 
excess salt, excess body weight, smoking, and alcohol) 
• The remaining 5–10% of cases are categorized as 
secondary HT, defined as HT due to an identifiable 
cause, such as chronic kidney disease, narrowing of 
the kidney arteries, an endocrine disorder, or the use 
of birth control pills 
https://en.wikipedia.org/wiki/Hypertension 
Etiology (?) 2   
http://www.dietkundali.com/images/hypertension.jpg 
Mechanisms 1 
(The Control Of Blood Pressure Systems )   
• Neurogenic  
• Renin-angiotensin  
• Atrial natriuretic peptide 
• Eicosanoids 
• Kallikrein-kinin 
• Endothelial  
• Adrenal steroids 
• Renomedullary vasodepression 
• Sodium and water excretion 
http://ceaccp.oxfordjournals.org/content/4/3/71.full 
Mechanisms 2 
(Multifactorial And Highly Complex) 
• Humoral mediators 
• Vascular reactivity 
• Circulating blood volume 
• Vascular caliber 
• Blood viscosity 
• Cardiac output 
• Blood vessel elasticity 
• Neural stimulation 
 
http://emedicine.medscape.com/article/1937383-overview 
Mechanisms 3  
(Key Points)  
http://image.slidesharecdn.com/hypertension2006path-bw-130410081448-phpapp01/95/hypertension-2013-pathophysiology-26-638.jpg?cb=1366765977 
Mechanisms 4 
(Short Term Nervous)  
http://images.slideplayer.com/1/245513/slides/slide_23.jpg 
Mechanisms 5 
(Long Term Humoral)   
http://image.slidesharecdn.com/hypertension2006path-bw-130410081448-phpapp01/95/hypertension-2013-pathophysiology-14-638.jpg?cb=1366765977 
Mechanisms 6  
(Combine Peripheral Humoral And Nervous) 
http://www.poweroverpressure.com/wcm/groups/mdtcom_sg/@mdt/documents/images/pop_angiotensin.gif 
Mechanisms 7 
(Nature of Resistant Hypertension)  
http://www.hindawi.com/journals/ijhy/2011/196518.fig.001.jpg 
Adaptation to Arterial Hypertension 
It lies on the surface (cardiac and vascular remodelling) 
• Cardiac  
• structural remodeling of the left ventricle 
• wall thickening (ventricular hypertrophy) 
• luminal dilatation 
• Vascular  
•  structural remodeling of muscular and elastic arteries 
• wall thickening (hypertrophy) 
• luminal dilatation  
In reality changes take place in all systems and structures 
http://circ.ahajournals.org/content/86/6/1909.full.pdf 
Classification 
(European Society of Cardiology) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Blood Pressure 
Classification 
Systolic blood pressure 
(mm Hg) 
Diastolic blood pressure 
(mm Hg) 
Normal < 120 < 80 
Pre-hypertension 120-139 80-89 
Stage 1 hypertension 140-159 90-99 
Stage 2 hypertension > 160 > 100 
Chobanian AV et al. JAMA 2003;289:2560-72. 
Classification 
(JNC-7 Blood Pressure Classification) 
Classification  
(Due to Cause) 
• Essential HT     up to 95% 
• Secondary (inessential) HT  
– Renovascular ( fibromuscular dysplasia, atheromatous 
stenosis, diabetes) 
– Secondary to other renal disorders (cronic renal failure, 
renal artery stenosis, renal segmental hypoplasia  
– Secondary to endocrine disorders 
(pheochromocytoma,  hyperaldosteronism (Conn's 
syndrome), Cushing's syndrome, hyperparathyroidism, 
acromegaly, hyperthyroidism, hypothyroidism) 
– Other (hormonal contraceptives, neurologic disorders, 
obstructive sleep apnea, liquorice, scleroderma, 
neurofibromatosis, pregnancy, cancers, drugs, etc.) 
en.wikipedia.org/wiki/Secondary_hypertension 
Classification  
(Resistant HT) 
• Resistant HT is defined as HT that remains above goal blood 
pressure in spite of using, at once, three antihypertensive 
medications belonging to different drug classes 
• Low adherence to treatment is an important cause of resistant 
HT 
• Resistant HT may also represent the result of chronic high 
activity of the autonomic nervous system (neurogenic 
hypertension) 
https://en.wikipedia.org/wiki/Hypertension 
Clinical Investigation  
(Symptoms) 
• HT is rarely accompanied by any symptoms, and its 
identification is usually through screening, or when 
seeking healthcare for an unrelated problem 
• Some with high blood pressure report headaches 
(particularly at the back of the head and in the 
morning), as well as lightheadedness, vertigo, tinnitus 
(buzzing or hissing in the ears), altered vision 
or fainting episodes 
• These symptoms, however, might be related to 
associated anxiety rather than the high blood pressure 
itself 
 en.wikipedia.org/wiki/Hypertension 
Clinical Investigation  
(Physical Examination) 
• Physical examination aims to establish or verify the diagnosis of 
HT, establish current BP, screen for secondary causes of HT and 
refine global CV risk estimation 
• BP should be repeatedly measured to confirm the diagnosis of HT  
• All patients should undergo auscultation of the carotid arteries, 
heart and renal arteries 
• Murmurs should suggest further investigation (carotid ultrasound, 
echocardiography, renal vascular ultrasound, depending on the 
location of the murmur) 
• Height, weight, and waist circumference should be measured 
with the patient standing, and BMI calculated 
• Pulse palpation and cardiac auscultation may reveal arrhythmias 
• Heart rate should be measured while the patient is at rest  
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Clinical Investigation  
(Physical Examination: Signs of Secondary HT ) 
• Features of Cushing syndrome 
• Skin stigmata of  neurofibromatosis (pheochromocytoma) 
• Palpation of enlarged kidneys (polycystic kidney) 
• Auscultation of abdominal murmurs (renovascular hypertension) 
• Auscultation of precordial or chest murmurs (aortic coarctation; 
aortic disease; upper extremity artery disease) 
• Diminished and delayed femoral pulses and reduced femoral 
blood pressure compared to simultaneous arm BP (aortic 
coarctation; aortic disease; lower extremity artery disease) 
• Left–right arm BP difference (aortic coarctation; subclavian artery 
stenosis) 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Clinical Investigation  
(Physical Examination: Signs of Organ Damage) 
• Brain: motor or sensory defects 
• Retina: fundoscopic abnormalities 
• Heart: heart rate, 3rd or 4th heart sound, heart murmurs, 
arrhythmias, location of apical impulse, pulmonary rales, 
peripheral oedema 
• Peripheral arteries: absence, reduction, or asymmetry of pulses, 
cold extremities, ischaemic skin lesions 
• Carotid arteries: systolic murmurs 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Clinical Investigation  
(Physical Examination: Evidence of Obesity) 
• Weight and height 
• Calculate BMI: body weight/height 2 (kg/m2 ) 
• Waist circumference measured in the standing position, at a level 
midway between the lower border of the costal margin (the 
lowest rib) and uppermost border of the iliac crest 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Clinical Investigation  
(Hypertensive Crisis) 
• Severely elevated blood pressure (equal to or greater than a 
SBP 180 or DBP 110) is referred to as a hypertensive crisis 
• Hypertensive crisis is categorized as either hypertensive 
urgency or hypertensive emergency, according to the absence 
or presence of end organ damage, respectively  
• In hypertensive urgency oral medications are used to lower the 
BP gradually over 24 to 48 hours  
• In hypertensive emergency, the BP must be reduced more 
rapidly to stop ongoing organ damage, however, there is a lack 
of randomised controlled trial evidence for this approach  
https://en.wikipedia.org/wiki/Hypertension 
Clinical Investigation  
(Outcomes) 
• HT is the most important preventable risk factor for premature 
death worldwide 
• HT increases the risk of ischemic heart disease, strokes, 
peripheral vascular disease, and other cardiovascular diseases, 
including heart failure, aortic aneurysms, 
diffuse atherosclerosis, chronic kidney disease, and pulmonary 
embolism 
• HT is also a risk factor for cognitive impairment and dementia 
• Other complications include hypertensive retinopathy 
and hypertensive nephropathy 
https://en.wikipedia.org/wiki/Hypertension 
Diagnosis 
  
• The evaluation of HT involves accurately measuring the 
patient’s blood pressure, performing a focused medical 
history and physical examination, and obtaining results of 
laboratory and instrumental studies 
• These steps can help determine the following: 
– Presence of end-organ disease 
– Possible causes of HT 
– Cardiovascular risk factors 
– Baseline values for judging biochemical effects of therapy  
 emedicine.medscape.com/article/241381-overview 
Diagnosis 
(Blood Pressure Measurement) 
  
• Office or clinic blood pressure 
• Out-of-office blood pressure 
– Ambulatory blood pressure monitoring 
– Home blood pressure monitoring 
• White-coat (or isolated office) HT     - 13% (range 9–16%) 
• Masked (or isolated ambulatory) HT - 13% (range 10–17%) 
 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Office and Out-of-Office Blood Pressure Criteria) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(from True Normotension to Sustained Hypertension) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(ABPM Derived Variables) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Total Cardiovascular Risk Stratification) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Risk Factors) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Asymptomatic Organ Damage) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Diabetes Mellitus) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Established Cardiovascular or Renal Disease) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(from Predictive Value to Cost–Effectiveness of Some 
Markers of Organ Damage) 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Routine Tests) 
• Hemoglobin and/or hematocrit 
• Fasting plasma glucose 
• Serum total cholesterol, low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol 
• Fasting serum triglycerides 
• Serum potassium and sodium 
• Serum uric acid 
• Serum creatinine (with estimation of GFR) 
• Urine analysis: microscopic examination; urinary protein by 
dipstick test; test for microalbuminuria 
• 12-lead ECG 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Additional Tests) 
• Hemoglobin A1c (if fasting plasma glucose is >5.6 mmol/L 
(102 mg/dL) or previous diagnosis of diabetes) 
• Quantitative proteinuria (if dipstick test is positive); urinary 
potassium and sodium concentration and their ratio 
• Home and 24-h ambulatory BP monitoring 
• Echocardiogram 
• Exercise testing, Holter monitoring in case of arrhythmias 
• Carotid ultrasound 
• Peripheral artery/abdominal ultrasound 
• Pulse wave velocity 
• Ankle-brachial index 
• Fundoscopy 
http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Diagnosis 
(Extended Evaluation) 
• Further search for cerebral, cardiac, renal, and vascular 
damage, mandatory in resistant and complicated 
hypertension 
• Search for secondary hypertension when suggested by history, 
physical examination, or routine and additional tests 
Treatment 
(Strategies) 
• Patient education  
• Lifestyle changes  
• Pharmacological therapy 
 
http://emedicine.medscape.com/article/198475-overview#a3  
Treatment 
(Lifestyle Changes) 
• Salt restriction  
• Moderation of alcohol consumption 
• Other dietary changes (vegetables, low-fat dairy 
products, dietary and soluble fibers, whole grains 
and protein from plant sources, reduced in 
saturated fat and cholesterol) 
• Weight reduction 
• Regular physical exercise 
• Smoking cessation  
 
http://emedicine.medscape.com/article/198475-overview#a3  
Treatment 
(Pharmacotherapy) 
• Diuretics (including thiazides, chlorthalidone and 
indapamide) 
• Beta-blockers  
• Calcium antagonists 
• Angiotensin-converting enzyme (ACE) inhibitors 
• Angiotensin receptor blockers  
• Renin inhibitors  
• Other antihypertensive agents (alpha-receptor 
blockers) 
• Monotherapy and combination therapy 
http://emedicine.medscape.com/article/198475-overview#a3  
US MLE  
1.A 56-year-old man comes to the clinic for a return visit. During his last 
three visits, he has had an elevated blood pressure in the range of 150-
160 mm Hg systolic pressure over 90-95 mm Hg diastolic. Despite 3-6 
months of a new diet and exercise program, he has not been able to get 
his blood pressure under control. His past medical history, except for his 
high blood pressure, is unremarkable. He is concerned about high blood 
pressure, as his older brother had high blood pressure and died from a 
heart attack in his mid 60s. Today his blood pressure is 162/92 mm Hg. 
Which of the following is the most appropriate, cost-effective, first-line 
treatment for this patient? 
 
A. Acetazolamide, B. Clonidine , C. Felodipine, D. Hydrochlorothiazide, E. 
Lisinopril, F. Metoprolol, G. None, continue diet and exercise, H. 
Spironolactone, I. Terazosin, J. Triamterene 
http://www.usmle-forums.com/usmle-step-2-ck-forum/16422-cardiology-5-questions-10-25-a.html 
US MLE  
A 62-year-old man comes to the clinic complaining of urinary 
hesitancy, 3-4 episodes of nocturia per night, and a weak urinary 
stream. His past medical history is significant for stage I 
hypertension that persists despite diet and exercise. Physical 
examination confirms the patient’s mild hypertension and a 
suspected enlarged, symmetric, and non-nodular prostate. In 
considering antihypertensive treatment, which of the following 
is a medication that can treat this patient’s urinary symptoms 
and his mild hypertension?  
 
A. Atenolol, B. Doxazosin, C. Felodipine, D. Finasteride, E. 
Hydrochlorothiazide 
http://www.usmle-forums.com/usmle-step-2-ck-forum/16422-cardiology-5-questions-10-25-a.html 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Treatment 
(Compelling and Possible Contra-Indications to the 
Use of Antihypertensive Drugs) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Treatment 
(Drugs to be Preferred in Specific Conditions) 
Treatment 
(Blood Pressure Goals) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
SBP goal for “most” 
•Patients at low–moderate CV risk 
•Patients with diabetes 
•Consider with previous stroke or TIA 
•Consider with CHD 
•Consider with diabetic or non-diabetic CKD 
<140 mmHg 
SBP goal for elderly 
•Ages <80 years 
•Initial SBP ≥160 mmHg 
140-150 mmHg 
SBP goal for fit elderly 
Aged <80 years 
<140 mmHg 
SBP goal for elderly >80 years with SBP 
•≥160 mmHg 
140-150 mmHg 
DBP goal for “most” <90 mmHg 
DB goal for patients with diabetes <85 mmHg 
Treatment 
(for People with Diabetes) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Recommendations Additonal considerations 
Mandatory: initiate drug treatment in 
patients with SBP ≥160 mmHg 
• Strongly recommended: start drug 
treatment when SBP ≥140 mmHg 
SBP goals for patients with diabetes: <140 mmHg 
DBP goals for patients with diabetes: <85 mmHg 
All hypertension treatment agents are 
recommended and may be used in 
patients with diabetes 
• RAS blockers may be preferred 
• Especially in presence of preoteinuria or 
microalbuminuria 
Choice of hypertension treatment must take comorbidities into account 
Coadministration of RAS blockers not 
recommended 
• Avoid in patients with diabetes 
SBP, systolic blood pressure; DBP, diastolic blood pressure; RAS, renin–angiotensin system. 
Treatment 
(for People with Nephropathy) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
SBP, systolic blood pressure; DBP, diastolic blood pressure; RAS, renin–angiotensin system. 
Recommendations Additonal considerations 
Consider lowering SBP to <140 mmHg 
Consider SBP <130 mmHg with overt 
proteinuria 
• Monitor changes in eGFR 
RAS blockers more effective to reduce 
albuminuria than other agents 
• Indicated in presence of 
microalbuminuria or overt proteinuria 
Combination therapy usually required 
to reach BP goals 
• Combine RAS blockers with other 
agents 
Combination of two RAS blockers • Not recommended 
Aldosterone antagonist not 
recommended in CKD 
• Especially in combination with a 
RAS blocker 
• Risk of excessive reduction in renal 
function, hyperkalemia 
JNC 8 ESH/ESC AHA/ACC ASH/ISH 
>140/90 
Threshold >140/90 < 60 yr Eldery SBP >160 >140/90 <80 yr 
for Drug Rx >150/90 >60 yr Consider SBP >140/90 >150/90 >80 yr 
140-150 if <80 yr 
B-blocker No Yes No No 
First line Rx 
Initiate Therapy >160/100 "Markedly >160/100 >160/100 
w/ 2 drugs elevated BP" 
Treatment 
(Comparison of Recent Guideline Statements) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Group BP Goal (mm Hg) 
General DM* CKD** 
JNC 8: <60 yr: <140/90 < 140/90 < 140/90 
>60 yr: <150/90 
ESH/ESC: < 140/90 < 140/85 < 140/90 
Elderly 140-150/90 (SBP < 130 if proteinuria) 
(<80 yr: SBP<140) 
ASH/ISH < 140/90 < 140/90 < 140/90 
>80 yr: <150/90 (Consider < 130/80 if proteinuria) 
AHA/ACC < 140/90 < 140/90 < 140/90 
*ADA: < 140/80 or lower **KDIGO: <140/90 w/o albuminuria <130/80 if >30 mg/24hr 
Treatment 
(Goal Blood Pressure) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Treatment 
(Monotherapy vs Drug Combination Therapy) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Treatment 
(Possible Combination  of Antihypertensive Drugs’ Classes) 
 eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 
Prognosis  
• Untreated HT is notorious for increasing the risk of mortality 
and is often described as a silent killer 
• Mild to moderate HT, if left untreated, may be associated with 
a risk of atherosclerotic disease in 30% of people and organ 
damage in 50% of people within 8-10 years after onset 
• Death from ischemic heart disease or stroke increases 
progressively as BP increases (for every 20 mm Hg systolic or 
10 mm Hg diastolic increase in BP above 115/75 mm Hg, the 
mortality rate for both ischemic heart disease and stroke 
doubles)  
http://emedicine.medscape.com/article/241381-overview#a6 
Prophylaxis 
• Population strategies are required to reduce the 
consequences of high BP and reduce the need for 
antihypertensive drug therapy 
• Lifestyle changes are recommended to lower BP, before 
starting drug therapy 
• Effective lifestyle modification may lower blood pressure as 
much as an individual antihypertensive drug 
• Combinations of two or more lifestyle modifications can 
achieve even better results  
https://en.wikipedia.org/wiki/Hypertension 
Abbreviations  
• ABP    - ambulatory blood pressure 
• ACE    - angiotensin converting enzyme 
• ARB    - angiotensin receptor blocker 
• AT      - angiotensin  
• BMI   - body mass index 
• BB      - beta blockers  
• BP      - blood pressure 
• CKD   - chronic kidney disease 
• CO     - carbon oxide 
• CV      - cardiovascular 
• DBP    - diastolic blood pressure 
• DM     - diabetes mellitus 
• ECG     - electrocardiography 
• GFR    - glomerular filtration rate 
• HDL-C –high density lipoprotein 
cholesterol 
• HIC     -high-income countries 
 
 
• HT      - arterial hypertension 
• LDL-C – low density lipoprotein 
cholesterol  
• LIC      -low-income countries  
• LMIC  - lower middle-income countries 
• LVH    - left ventricle hypertrophy 
• LVM   - left ventricle mass  
• NO     - nitrogen oxide 
• OD     - organ demige 
• RAAS – renin angiotensin aldosterone 
system 
• RF       - risk factors 
• RCTs   - randomized control trials 
• SBP    - systolic blood pressure 
• TC      - total cholesterol 
• TG     - triglycerides  
• UMIC - upper middle-income countries  
Diagnostic and treatment guidelines 
Europe 
• 2013 ESH/ESC Guidelines for the management of 
arterial hypertension 
• Hypertension - National Institute for Health and Care 
Excellence (nice) guidelines and related materials 
 
North America 
• 2014 Evidence-based guideline for the management of 
high blood pressure in adults. Report from the panel 
members appointed to the eighth joint national 
committee (JNC 8) 
• British Columbia guidelines on detection, diagnosis and 
management of hypertension [2015] 
 
 
 
